Medication prescribed to MS patients in the U.S. 2013

This statistic displays the percentage of disease-modifying therapies (DMTs) prescribed to multiple sclerosis patients as of 2013, as reported by neurologists. As of that year, 5.2 percent of patients were prescribed fingolimod.

Percentage of disease-modifying therapies (DMTs) prescribed to multiple sclerosis patients as of 2013*

Characteristic	Mean percentage of patients prescribed medication
Fingolimod	5.2%
Glatiramer acetate	28.7%
IM IFN β-1a	18.7%
SC IFN β-1a	18.8%
IFN β-1b	20.6%
Other**	7.7%
No DMTs	5.5%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

2014

More information

Region

United States

Survey time period

December 2012 to January 2013

Number of respondents

102 respondents

Special properties

general neurologists and MS specialists

Method of interview

Online survey

Supplementary notes

* Mean percentage. As reported by neurologists. Abbreviations: IM, intramuscular; IFN, interferon; SC , subcutaneous; DMTs, disease-modifying therapies.
** Includes patients on natalimumab (6.6%) and other medications (azathioprine, cladribine, cyclophosphamide, daclizumab, intravenous immunoglobulin, methotrexate, mycophenolate mofetil, naltrexone, rituximab, corticosteroids, teriflunimide [1.1% combined]).

Citation formats